Global Dengue Treatment Market  Cover

Global Dengue Treatment Market By Type (Drug and Vaccine), By Route of Administration (Oral, and Parenteral), By End-users (Hospitals, Specialty Clinic, Homecare, and Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa)

  • Report ID: HC-10
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 78
  • No. Of Pages: 227
  • Format:
  • Pub. Date: 2020-07-01
  • Share:

Market Outlook:

The global dengue treatment market was valued at US$ 296 Million in 2019 and is projected to reach US$ 727 Million by 2027 expanding at a CAGR of 13.3 % during the forecast period, 2021-2027. Dengue is the most rapidly spreading mosquito-borne viral disease in the world. Dengue fever, also known as break-bone fever, leads to severe flu. Dengue is caused by an RNA virus of mosquitos that belong to the Flaviviridae family and several other species of mosquitos such as Aedes. Symptoms of dengue include fever, headache vomiting, muscle, joint pain, and characteristic skin rash. The patient recovers from dengue within seven days; however, in some cases, it can develop into life-threatening dengue hemorrhagic fever. The global dengue treatment market is anticipated grow due to the rise in the burden of dengue in tropical and subtropical regions. Increase in government funding to fight against dengue and unmet market needs of managing this burden globally boosts the dengue treatment market.
 
dengue treatment market outlook
 

Market Dynamics

The market is driven by factors such as growing awareness about prevention and control of dengue, robust promising pipeline of manufacturers for dengue treatment, increasing prevalence of dengue. However, stringent government regulations regarding drug approval, and lack of government facilities and skilled medical professionals in under developed countries are the factors expected to hamper the market growth. Whereas, rising R&D investment and activities is expected to create lucrative opportunities in the market.
 

Segmental Outlook

On the basis of type, the global dengue treatment market is bifurcated into drug and vaccine. The drug segment is expected to holds a major share of the market, in terms of volume, due to easy availability and low cost prices. The vaccine segment is estimated to at a significant CAGR of around 35.3% during the forecast period.
 
dengue treatment market BPS analysis
 
Based on route of administration the global dengue treatment market is classified into oral, and parenteral. The parenteral segment is projected to hold a major share of the market due to their high cost and wide adoption, as patients need instant recovery from the dengue virus. This, in turn, increases the demand for the vaccine using parenteral route of the administration during the forecast period.
 
Dengue Treatment Market Attractiveness Analysis
 

Regional Outlook

In terms of region the market has been fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is a promising region for the market. It constituted around half of the market in terms of share in 2019. The market in the region is projected to expand at a CAGR of 14.0 % during the forecast period. The demand for dengue treatment is expected to rise due to the rapid increase in prevalence of dengue in the region during the forecast period.
 
Dengue Treatment Market Regional Analysis
 

Competitive Landscape

  • Key players in the market include Sanofi, and Johnson & Johnson Services, Inc. These companies are considered as key manufacturers of dengue treatment based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
  • The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the dengue treatment extraction is added in the company’s capacity.
  • For instance, in February 2020, Johnson & Johnson Services, Inc. announced that its subsidary Janssen Pharmaceutical Companies is further accelerating its investigational coronavirus vaccine program by collaborating with the Biomedical Advanced Research & Development Authority (BARDA), a part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health & Human Services.
  • In December 2018, Merck & Co., Inc., and Instituto Butantan, a non-profit producer of immunobiologic products for Brazil entered into a collaborative agreement to develop vaccines to protect against dengue virus disease, the mosquito-borne infection. Instituto Butantan and Merck & Co., Inc. have licensed certain rights from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S National Institutes of Health (NIH), for the development of live attenuated tetravalent vaccines (LATVs).
     
Dengue Treatment Market Kay Player Analysis
 

Key Benefits for Industry Participants & Stakeholders

  • In-depth Analysis of the Global Dengue Treatment Market
  • Historical, Current and Projected Market Size in terms of Value and Volume
  • Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
  • Industry Drivers, Restraints and Opportunities Covered in the Study
  • Recent Industry Trends and Developments
  • Competitive Landscape & Strategies of Key Players
  • Neutral Perspective on Global Dengue Treatment Market Performance

 
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dengue Treatment Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Dengue Treatment Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Dengue Treatment Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Pipeline Analysis
   4.5 Global Dengue Treatment Market Size & Forecast, 2017-2027
      4.5.1 Dengue Treatment Market Size and Y-o-Y Growth
      4.5.2 Dengue Treatment Market Absolute $ Opportunity
   4.6 Pricing Analysis & Forecast, 2017-2027

   4.7 Travellers Data
Chapter 5 Global Dengue Treatment Market Analysis and Forecast By Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Type
      5.1.2 Basis Point Share (BPS) Analysis By Type
      5.1.3 Absolute $ Opportunity Assessment By Type
   5.2 Dengue Treatment Market Size & Volume Forecast By Type
      5.2.1 Drug
      5.2.2 Vaccines
   5.3 Market Attractiveness Analysis By Type

Chapter 6 Global Dengue Treatment Market Analysis and Forecast By Route of Administration
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Route of Administration
      6.1.2 Basis Point Share (BPS) Analysis By Route of Administration
      6.1.3 Absolute $ Opportunity Assessment By Route of Administration
   6.2 Dengue Treatment Market Size & Volume Forecast By Route of Administration
      6.2.1 Oral
      6.2.2 Parenteral
   6.3 Market Attractiveness Analysis By Route of Administration
Chapter 7 Global Dengue Treatment Market Analysis and Forecast By End-user
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By End-user
      7.1.2 Basis Point Share (BPS) Analysis By End-user
      7.1.3 Absolute $ Opportunity Assessment By End-user
   7.2 Dengue Treatment Market Size & Volume Forecast By End-user
      7.2.1 Hospitals
      7.2.2 Homecare
      7.2.3 Specialty Clinics
      7.2.4 Others
   7.3 Market Attractiveness Analysis By End-user
Chapter 8 Global Dengue Treatment Market Analysis and Forecast by Region
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities by Region
      8.1.2 Basis Point Share (BPS) Analysis by Region
      8.1.3 Absolute $ Opportunity Assessment by Region
   8.2 Dengue Treatment Market Size Forecast by Region
      8.2.1 North America
      8.2.2 Europe
      8.2.3 Asia Pacific
      8.2.4 Latin America
      8.2.5 Middle East & Africa (MEA)
   8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
   9.1 Introduction
   9.2 Current & Future Impact Analysis
   9.3 Economic Impact Analysis
   9.4 Government Policies
   9.5 Investment Scenario
Chapter 10 North America Dengue Treatment Analysis and Forecast
   10.1 Introduction
   10.2 North America Dengue Treatment Market Size Forecast by Country
      10.2.1 U.S.
      10.2.2 Canada
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 North America Dengue Treatment Market Size & Volume Forecast By Type
      10.6.1 Drug
      10.6.2 Vaccines
   10.7 Basis Point Share (BPS) Analysis By Type
   10.8 Absolute $ Opportunity Assessment By Type
   10.9 Market Attractiveness Analysis By Type
   10.10 North America Dengue Treatment Market Size & Volume Forecast By Route of Administration
      10.10.1 Oral
      10.10.2 Parenteral
   10.11 Basis Point Share (BPS) Analysis By Route of Administration
   10.12 Absolute $ Opportunity Assessment By Route of Administration
   10.13 Market Attractiveness Analysis By Route of Administration
   10.14 North America Dengue Treatment Market Size & Volume Forecast By End-user
      10.14.1 Hospitals
      10.14.2 Homecare
      10.14.3 Specialty Clinics
      10.14.4 Others
   10.15 Basis Point Share (BPS) Analysis By End-user
   10.16 Absolute $ Opportunity Assessment By End-user
   10.17 Market Attractiveness Analysis By End-user
Chapter 11 Europe Dengue Treatment Analysis and Forecast
   11.1 Introduction
   11.2 Europe Dengue Treatment Market Size Forecast by Country
      11.2.1 Germany
      11.2.2 France
      11.2.3 Italy
      11.2.4 U.K.
      11.2.5 Spain
      11.2.6 Russia
      11.2.7 Rest of Europe
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Europe Dengue Treatment Market Size & Volume Forecast By Type
      11.6.1 Drug
      11.6.2 Vaccines
   11.7 Basis Point Share (BPS) Analysis By Type
   11.8 Absolute $ Opportunity Assessment By Type
   11.9 Market Attractiveness Analysis By Type
   11.10 Europe Dengue Treatment Market Size & Volume Forecast By Route of Administration
      11.10.1 Oral
      11.10.2 Parenteral
   11.11 Basis Point Share (BPS) Analysis By Route of Administration
   11.12 Absolute $ Opportunity Assessment By Route of Administration
   11.13 Market Attractiveness Analysis By Route of Administration
   11.14 Europe Dengue Treatment Market Size & Volume Forecast By End-user
      11.14.1 Hospitals
      11.14.2 Homecare
      11.14.3 Specialty Clinics
      11.14.4 Others
   11.15 Basis Point Share (BPS) Analysis By End-user
   11.16 Absolute $ Opportunity Assessment By End-user
   11.17 Market Attractiveness Analysis By End-user
Chapter 12 Asia Pacific Dengue Treatment Analysis and Forecast
   12.1 Introduction
   12.2 Asia Pacific Dengue Treatment Market Size Forecast by Country
      12.2.1 China
      12.2.2 Japan
      12.2.3 South Korea
      12.2.4 India
      12.2.5 Australia
      12.2.6 Rest of Asia Pacific (APAC)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Asia Pacific Dengue Treatment Market Size & Volume Forecast By Type
      12.6.1 Drug
      12.6.2 Vaccines
   12.7 Basis Point Share (BPS) Analysis By Type
   12.8 Absolute $ Opportunity Assessment By Type
   12.9 Market Attractiveness Analysis By Type
   12.10 Asia Pacific Dengue Treatment Market Size & Volume Forecast By Route of Administration
      12.10.1 Oral
      12.10.2 Parenteral
   12.11 Basis Point Share (BPS) Analysis By Route of Administration
   12.12 Absolute $ Opportunity Assessment By Route of Administration
   12.13 Market Attractiveness Analysis By Route of Administration
   12.14 Asia Pacific Dengue Treatment Market Size & Volume Forecast By End-user
      12.14.1 Hospitals
      12.14.2 Homecare
      12.14.3 Specialty Clinics
      12.14.4 Others
   12.15 Basis Point Share (BPS) Analysis By End-user
   12.16 Absolute $ Opportunity Assessment By End-user
   12.17 Market Attractiveness Analysis By End-user
Chapter 13 Latin America Dengue Treatment Analysis and Forecast
   13.1 Introduction
   13.2 Latin America Dengue Treatment Market Size Forecast by Country
      13.2.1 Brazil
      13.2.2 Mexico
      13.2.3 Rest of Latin America (LATAM)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Latin America Dengue Treatment Market Size & Volume Forecast By Type
      13.6.1 Drug
      13.6.2 Vaccines
   13.7 Basis Point Share (BPS) Analysis By Type
   13.8 Absolute $ Opportunity Assessment By Type
   13.9 Market Attractiveness Analysis By Type
   13.10 Latin America Dengue Treatment Market Size & Volume Forecast By Route of Administration
      13.10.1 Oral
      13.10.2 Parenteral
   13.11 Basis Point Share (BPS) Analysis By Route of Administration
   13.12 Absolute $ Opportunity Assessment By Route of Administration
   13.13 Market Attractiveness Analysis By Route of Administration
   13.14 Latin America Dengue Treatment Market Size & Volume Forecast By End-user
      13.14.1 Hospitals
      13.14.2 Homecare
      13.14.3 Specialty Clinics
      13.14.4 Others
   13.15 Basis Point Share (BPS) Analysis By End-user
   13.16 Absolute $ Opportunity Assessment By End-user
   13.17 Market Attractiveness Analysis By End-user
Chapter 14 Middle East & Africa (MEA) Dengue Treatment Analysis and Forecast
   14.1 Introduction
   14.2 Middle East & Africa (MEA) Dengue Treatment Market Size Forecast by Country
      14.2.1 Saudi Arabia
      14.2.2 South Africa
      14.2.3 UAE
      14.2.4 Rest of Middle East & Africa (MEA)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Middle East & Africa (MEA) Dengue Treatment Market Size & Volume Forecast By Type
      14.6.1 Drug
      14.6.2 Vaccines
   14.7 Basis Point Share (BPS) Analysis By Type
   14.8 Absolute $ Opportunity Assessment By Type
   14.9 Market Attractiveness Analysis By Type
   14.10 Middle East & Africa (MEA) Dengue Treatment Market Size & Volume Forecast By Route of Administration
      14.10.1 Oral
      14.10.2 Parenteral
   14.11 Basis Point Share (BPS) Analysis By Route of Administration
   14.12 Absolute $ Opportunity Assessment By Route of Administration
   14.13 Market Attractiveness Analysis By Route of Administration
   14.14 Middle East & Africa (MEA) Dengue Treatment Market Size & Volume Forecast By End-user
      14.14.1 Hospitals
      14.14.2 Homecare
      14.14.3 Specialty Clinics
      14.14.4 Others
   14.15 Basis Point Share (BPS) Analysis By End-user
   14.16 Absolute $ Opportunity Assessment By End-user
   14.17 Market Attractiveness Analysis By End-user
Chapter 15 Competition Landscape
   15.1 Dengue Treatment Market: Competitive Dashboard
   15.2 Global Dengue Treatment Market: Market Share Analysis, 2019
   15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      15.3.1 GeneOne Life Science, Inc
      15.3.2 Johnson & Johnson
      15.3.3 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      15.3.4 Novartis AG
      15.3.5 Sanofi
      15.3.6 Serum Institute of India Pvt. Ltd
      15.3.7 Sun Pharmaceutical Industries Ltd.
      15.3.8 Takeda Pharmaceutical Company Limited

Key Segments Covered

By Type
  • Drug
  • Vaccine
By Route of Administration
  • Oral
  • Parenteral
By End-user
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • France
    • Italy
    • UK
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of MEA
Key Market Players Profiled in the Report
  • GeneOne Life Science, Inc
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited

Buy Report

FAQ Section

Some frequently asked quetions about this report!

Additional company profiles can be provided on request.

Yes, the report includes the traveler’s data in the final report. The data is provided as per the data availability and dengue cases reported in particular countries.

According to this Growth Market Reports report, the market from dengue treatment is likely to register a CAGR of 13.3% during forecast period 2020-2027, with an anticipated valuation of US$ 727 million by the end of the 2027.

In addition to market size (in US$ Million), Market Volume (in Million unit), and Company Market Share (in % for base year 2019), other data such as Pricing analysis for year 2017 to 2027 (estimated pricing analysis) is provided, Pipeline Analysis for dengue treatment is also available in final report.

The increasing government initiatives to fight against dengue, promising dengue pipeline, growing prevalence of dengue, and rising awareness of dengue are the factors expected to drive the market growth during forecast period.

Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.

The market is expected to witness decline of over 0.6% between 2019 and 2020 owing to the negative impact of COVID 19 pandemic on the dengue treatments market. The shutdown of production activities, restrictions on transportation activities, and temporary decline in demand for dengue treatments are some of the prime reasons responsible for this market trend.

The base year considered for the global dengue treatment market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027

Hospitals and Homecare are the key end-users driving the dengue treatment market.

Major manufactures include, Sanofi, and Johnson & Johnson Services, Inc.